Monopar gets rights to Onxeo's Validive

Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO) granted Monopar Therapeutics Inc. (Northbrook, Ill.) exclusive, worldwide rights to Validive clonidine lauriad (BA-028). Onxeo will receive a $1 million license fee and is eligible for $108 million in milestones, including $15.5 million for regulatory milestones. Onxeo is also eligible for royalties up to double digits...